Thursday, January 28, 2021

08:00–08:05 Welcome

SESSION I – Etiology of MDS
Chairs: Charlotte Niemeyer (Freiburg) & Austin Kulasekararaj (London)

08:05–08:20 Therapy related MDS and other environmental factors in MDS
     Discussion
     Maria Teresa Voso (Rome)

08:20–08:25

08:25–08:40 Genetic predisposition to MDS and acute leukemia
     Discussion
     Charlotte Niemeyer (Freiburg)

08:40–08:45

08:45–09:00 CHIP / functional implications in MDS and AML
     Discussion
     Austin Kulasekararaj (London)

09:00–09:05

09:05–09:20 Inflammation of HSCs as a potential driver of ineffective hematopoiesis
     Discussion
     Marieke Essers (Heidelberg)

09:20–09:25

09:25–09:40 Relationships between inherited and acquired predisposition
     Discussion
     Jaroslaw Maciejewski (Cleveland)

09:40–09:45

09:45–09:52 Short communication
     Discussion
     Speaker

09:52–09:55

09:55–10:02 Short communication
     Discussion
     Speaker

10:02–10:05

10:05–10:35 Panel discussion

10:35–11:05 Coffee Break
SESSION II – Biology of MDS – Genetic Abnormalities
Chairs: Maria (Ken) Figueroa (Miami) & Mikkael Sekeres (Cleveland)

11:05-11:20 Review of currently available pre-clinical models (including zebra fish) of MDS
Daniel Nowak (Mannheim)

11:20-11:25 Discussion

11:25-11:40 Multiple acquired clonal steps to MDS, molecular architecture and its progression to AML
Olivier Kosmider (Paris)

11:40-11:45 Discussion

11:45-12:00 Druggable molecular targets in MDS and elderly AML (IDH, TP53...)
Torsten Haferlach (Munich)

12:00-12:05 Discussion

12:05-12:20 Epigenetic abnormalities in MDS and their relationship with somatic mutations
Maria (Ken) Figueroa (Miami)

12:20-12:25 Discussion

12:25-12:40 Spliceosome mutations and their consequences in MDS?
Austin Kulasekararaj (London)

12:40-12:45 Discussion

12:45-12:52 Short communication
Speaker

12:52-12:55 Discussion

12:55-13:15 Panel discussion

13:15-14:55 Lunch

13:45-14:45 Possible slot for a satellite symposium (No longer available)

SESSION III – Biology of MDS: Stem Cells and the Microenvironment
Chairs: Hind Medyouf (Frankfurt) & Uwe Platzbecker (Leipzig)

14:55-15:10 The niche in MDS: Inflammation driving evolution
Marc H.G.P. Raaijmakers (Rotterdam)

15:10-15:15 Discussion

15:15-15:30 Bone biology and the osteo-hematopoietic niche
Lorenz C. Hofbauer (Dresden)*

15:30-15:35 Discussion

15:35-15:50 Hematopoietic stem cells in MDS: The real targets?
Ulrich Steidl (New York)

15:50-15:55 Discussion

15:55-16:10 Mesenchymal stem cells in MDS: The better targets?
Hind Medyouf (Frankfurt)

16:10-16:15 Discussion

16:15-16:30 Immunological mess in MDS; is there a target?
Shahram Kordasti (London)

16:30-16:35 Discussion
16:35-17:05  Controversial debate  
Chairs: TBA  
Genetics versus epigenetics in myeloid disease

16:35-16:45  Genetics  
Torsten Haferlach (Munich)  
16:45-16:55  Epigenetics  
Maria (Ken) Figueroa (Miami)  
16:55-17:05  Discussion

17:05-17:35  Coffee break

SESSION IV – Diagnostic Workup and Prognostic Factors in MDS  
Chairs: Ari Giagounidis (Düsseldorf) & Felicitas Thol (Hannover)

17:35-17:50  Morphology (including WHO 2018 classification), cytogenetics and flow cytometry  
Ari Giagounidis (Düsseldorf)  
17:50-17:55  Discussion

17:55-18:10  Examining prognostic indicators in MDS  
Heinz Tüchler (Vienna)  
18:10-18:15  Discussion

18:15-18:30  Role of comorbidities and quality of life in prognosis. New evaluation scales (QUALMS...)  
Reinhard Stauder (Innsbruck)  
18:30-18:35  Discussion

18:35-19:05  Round table on Response criteria (with recent proposed changes, IWG 2018)  
Uwe Platzbecker, Pierre Fenaux, Austin Kulasekararaj, Mikkael Sekkeres

19:05-19:35  DEBATE: IS NGS useful in MDS?  
No – Guillermo Sanz (Valencia)  
Yes – Felicitas Thol (Hannover)

19:40  Poster walks and stand up Get-Together buffet dinner for all)

Friday, January 29, 2021

08:00-09:00  3 Simultaneous Meet the Expert sessions (non-clinical)  
Flow cytometry in MDS  
Arjan Van de Lossdrecht (Amsterdam)  
Technical aspects  
Jaroslaw Maciejewski (Cleveland)  
Analysis of somatic mutations, of SNP etc.  
Luca Malcovati (Pavia)

08:00-09:00  Possible slot for a satellite symposium

SESSION V – Specific Subtypes of MDS, based on Morphology and Molecular Biology  
Chairs: Michaela Fontenay (Paris) & Eric Solary (Villejuif)

09:00-09:15  MDS with Ring sideroblasts  
Michaela Fontenay (Paris)  
09:15-09:20  Discussion
SESSION VI – Treatment of MDS
Chairs: Eva Hellström-Lindberg (Stockholm) & Raphael Itzykson (Paris)

11:20-11:35 Overview of MDS treatment
11:35-11:40 Discussion
Eva Hellström-Lindberg (Stockholm)

11:40-11:55 ESA and other growth factors
11:55-12:00 Discussion
Valeria Santini (Firenze)

12:00-12:15 HMAs: When and how
12:15-12:20 Discussion
Mikkael Sekeres (Cleveland)

12:20-12:35 Allo Transplantation: when and how?
12:35-12:40 Discussion
Marie Robin (Paris)

12:40-12:55 Current treatment guidelines for CMML and rare subtypes
12:55-13:00 Discussion
Raphael Itzykson (Paris)

13:00-13:07 Short communication
13:07-13:10 Discussion
Speaker

13:10-13:30 Panel discussion

13:30-15:10 Lunch

14:00-15:00 Possible slot for a satellite symposium (No longer available)

SESSION VII – Current Progress in the Treatment of MDS
Chairs: Valeria Santini (Firenze) & Lionel Adès (Paris)

15:25-15:30 Discussion
Lionel Adès (Paris)

A renewed role for intensive chemotherapy (CPX 351...)?
15:30-15:45  Strategies to improve HMA based therapy          Pierre Fenaux (Paris)
15:45-15:50  Discussion

15:50-16:20  Coffee break

16:20-16:35  Management of HMA failure                   Valeria Santini (Firenze)
16:35-16:40  Discussion

16:40-16:55  Novel strategies to treat cytopenia in Low Risk MDS Uwe Platzbecker (Leipzig)
16:55-17:00  Discussion

17:00-17:07  Short communication                        Speaker
17:07-17:10  Discussion

17:10-17:30  Panel discussion

Saturday, January 30, 2021

07:30-08:30  3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)
             Treatment of higher risk MDS                   Mikkael Sekeres (Cleveland)
             Treatment of lower risk MDS                   Lionel Adès (Paris)

SESSION VIII – Future Treatments and Treatment Strategies in MDS?
Chairs: Maria Diez Campelo (Salamanca) & Pierre Fenaux (Paris)

08:30-08:45  Regulatory issues: registration of drugs in haematology Axel Glasmacher (Bonn)
08:45-08:50  Discussion

08:50-09:30  Current MDS/CMML clinical trials in Europe and North America
             Speakers: Valeria Santini (FISM), Maria Diaz Campelo (GESMD), Pierre Fenaux (GFM),
                        Uwe Platzbecker (GMDS and EMSCO), M Sekeres (US MDS consortium)
09:30-09:35  Discussion

09:35-09:50  How to target CHIP?                          Klaus Metzeler (Munich)
09:50-09:55  Discussion

09:55-10:02  Short communication                        Speaker
10:02-10:05  Discussion

10:05-10:25  Panel discussion

10:25-10:55  Coffee break

SESSION IX – “Late-Breaking” talks or a”Late-Breaking” session
Chairs: Maria Diez Campelo (Salamanca) & Pierre Fenaux (Paris)

10:55-11:10  Title                                      Speaker
11:10-11:15  Discussion
11:15-11:30 Title
11:30-11:35 Discussion

11:35-11:55 Closing Remarks

*Pending confirmation